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Background: Brain metastases reduce survival because therapeutic options are limited. This phase II study
evaluated the efficacy of single-agent therapy with alternating weekly, dose-dense temozolomide in pretreated
patients with brain metastases prospectively stratified by primary tumor type.
Methods: Eligible patients had bidimensionally measurable brain metastases from histologically/cytologically
confirmed melanoma, breast cancer (BC), or non-small-cell lung cancer (NSCLC). Prior chemotherapy, radiotherapy,
and whole-brain radiotherapy (WBRT) were allowed. Patients received temozolomide 150 mg/m2/day (days 1–7 and
15–21 every 28- or 35-day cycle).
Results: In the intent-to-treat population (N = 157; 53 melanoma, 51 BC, and 53 NSCLC), one patient had complete
response, nine (6%) had partial responses, and 31 (20%) had stable disease in the brain. Median progression-free
survival was 56, 58, and 66 days for melanoma, BC, and NSCLC, respectively. Median overall survival was 100 days
for melanoma, 172 days for NSCLC, and not evaluable in the BC group. Thrombocytopenia was the most common
adverse event causing dose modification or treatment discontinuation. Grade 4 toxic effects were rare.
Conclusions: This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in
heavily pretreated patients with brain metastases, particularly in patients with melanoma. Combining temozolomide
with WBRT or other agents may improve clinical outcomes.
Key words: brain metastases, breast cancer, dose dense, melanoma, NSCLC, temozolomide
introduction
It is estimated that 8%–10% of patients with advanced cancer
will develop symptomatic brain metastases at some point
during the course of their disease [1–3]. Brain metastases are
particularly frequent in cancers of the lung (40%–50%), breast
(15%–25%), and in melanoma (5%–20%) and increasingly are
being diagnosed because of advancements in imaging
techniques and better control of primary systemic disease
resulting in improved survival [3]. Brain metastases are
associated with a poor prognosis; without treatment, median
survival is 1–2 months [4]. Standard of care for brain
metastases is whole-brain radiotherapy (WBRT), stereotactic
radiosurgery, or surgery [3]. Median survival achieved with
WBRT is 3–4 months [3]. A pioneering study (N = 1200)
evaluating prognostic factors associated with survival in
patients with brain metastases treated with radiation therapy
concluded that survival ranged from 7.1 months in patients
with Karnofsky performance status (KPS) ‡70, <65 years old,
controlled systemic disease, and brain as the only site of
metastases [Recursive Partitioning Analysis (RPA) class I],
compared with 4.2 months in patients categorized as RPA class
II, to 2.3 months in patients with KPS <70 with uncontrolled
systemic disease (RPA class III) [5, 6]. Numerous trials have
explored systemic chemotherapy, including temozolomide,
taxane/platinum regimens, vinorelbine/gemcitabine, and
topotecan either alone or in combination with WBRT [7–9].
Median overall survival (OS) in these studies ranged from 4.5
to 6.6 months, and most of these patients had brain metastases
from lung cancer. Clinical benefit data in patients with brain
metastases originating from other malignancies are limited.
Temozolomide is a second-generation, oral alkylating agent
with excellent central nervous system (CNS) bioavailability and
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proven activity against primary brain tumors [10–13]. In
addition, temozolomide is well tolerated, and hematologic
toxicity is usually noncumulative. O6-methylguanine-DNA
methyltransferase (MGMT) is a key DNA repair enzyme
responsible for tumor resistance to alkylating agents [14, 15].
Based on studies by Tolcher et al. [16] showing that dose-dense
regimens of temozolomide (including the alternating weekly
regimen) deplete MGMT levels in peripheral blood
mononuclear cells, it has been hypothesized that dose-dense
temozolomide may deplete MGMT in tumor cells and increase
antitumor activity. Accordingly, several clinical trials have
evaluated dose-dense temozolomide regimens in patients with
primary brain tumors [17, 18].
Previous studies of systemic chemotherapy for brain
metastases have largely enrolled patients with non-small-cell
lung cancer (NSCLC) along with small numbers of patients
with breast cancer (BC) and melanoma [7, 8, 19–23]. No
systematic studies have examined the benefit of temozolomide
in patients prospectively stratified by primary malignancy. The
present study examined clinical benefit and safety of an
alternating weekly (7/14-day), dose-dense temozolomide
regimen in patients with brain metastases from melanoma or
from breast or lung cancer that were not amenable to surgery or
radiosurgery. Patients were prospectively stratified by their
primary tumor type.
methods
patients
inclusion criteria. Patients with a cytologic/histologic diagnosis of NSCLC
(first or second line), malignant melanoma (first or second line), or BC and
one or more measurable brain metastases ‡1 cm in diameter were eligible.
Eligible patients must have completed previous anticancer therapy at least 4
weeks before study entry. All enrolled patients had an Eastern Cooperative
Oncology Group performance status of zero to two and acceptable
hematologic (leukocytes ‡ 3.5 · 109 cells/l; platelets ‡ 100 · 109 cells/l),
liver (bilirubin £ 25 lM), and renal (creatinine £ 150 lM; creatinine
clearance ‡ 60 ml/min) function. After the third and only substantial
amendment, inclusion criteria were extended to include irradiated brain
metastases. The final and approved protocol and informed consent were
reviewed and approved by the local ethics committee. The study was
conducted according to the tenets of the Declaration of Helsinki.
exclusion criteria. Before the third amendment, patients were excluded if
they had received prior WBRT for brain metastases; however, after the third
amendment, WBRT for brain metastases was allowed if completed ‡2
months before study entry. Patients with brain metastases amenable to
neurosurgery/radiosurgery were excluded; however, residual or
progressive malignant disease after neurosurgery was allowed. Patients
with diabetes precluding administration of adequate doses of
dexamethasone and patients requiring chronic anticonvulsant therapy were
also excluded.
study design
This was a multicenter, open-label, two-step, phase II trial, and patients
were prospectively stratified by primary tumor type. The primary end point
was clinical benefit, defined as best radiologic response [including complete
response (CR), partial response (PR), or stable disease (SD)] achieved
during the study period. Secondary end points included progression-free
survival (PFS), neurological progression-free survival (NPFS), OS, and
safety.
assessments. Baseline measurements of the brain included either magnetic
resonance imaging (MRI), with or without gadolinium enhancement, or
computed tomography (CT). In cases where a brain lesion diagnosis was
not equivocal, a radiolabeled leukocyte brain scan (HexaMethylPropylene
Amine Oxime 99Tc brain single-photon emission computed tomography)
was carried out to rule out infectious disease and improve diagnostic
accuracy. At baseline, after the first 2 months of treatment, and every 3
months thereafter, clinical and radiologic (CT or MRI) evaluation of brain
and other sites of disease was carried out until disease progression. Other
baseline measurements included physical examination, hematology, and
biochemistry. During study treatment, a CT or an MRI of the brain was
carried out every two cycles until disease progression. After the third
amendment, a radiologic confirmation of response after 4 weeks was
introduced in case of response or SD. Tumor response was evaluated on the
basis of World Health Organization response criteria [24]. The best
response during study treatment was reported. Response duration was
monitored, and responses maintained for at least 4 weeks as evaluated by
a sequential CT scan or MRI were recorded. Adverse events (AEs) were
graded according to the National Cancer Institute—Common Terminology
Criteria for Adverse Events (NCI-CTCAE) v3.0.
treatment. Patients received temozolomide orally, in a fasting state, at
a starting dose of 150 mg/m2 once daily for seven consecutive days repeated
every other week [days 1–7 and 15–21 of every 28-day cycle (schedule A)].
The treatment schedule was altered for all patients enrolled after the third
amendment to include seven additional days of rest from days 22 to 35,
increasing the cycle length to 35 days (schedule B). Treatment was
continued until either unacceptable toxicity or disease progression.
Dexamethasone was administered daily at a dose of 2–16 mg i.m. or i.v. for
the first 2 months; thereafter, an optimal dose of dexamethasone necessary
to maintain stable neurological symptoms was administered. In the event of
an absolute neutrophil count (ANC) <1500 cells/ll or a platelet
count <100 000/ll at any time while on therapy, treatment was delayed
until recovery to ANC ‡1500 cells/ll and platelet count ‡100 000/ll. The
dose was reduced to 125 mg/m2/day if ANC was <500 cells/ll for 5 days, if
ANC was <500 cells/ll with fever and/or platelet count <25 000/ll, or if
therapy was delayed by ‡2 weeks. In the event of NCI-CTCAE grade 3 or 4
non-hematologic toxicity, including gastrointestinal toxicity unresponsive
to standard therapy, dosing was delayed until toxicity resolved to baseline
or grade 1. Dose reduction to the next lower dose level was also
recommended.
statistical analysis. Following the Simon optimal two-stage design for phase
II studies, the trial was designed to refuse a clinical benefit rate £10%
(minimal benefit rate required to continue study after completion of first
step) and to provide 90% statistical power for assessing therapeutic activity
of a clinical benefit rate of 25% with an alpha error <0.05. Double data
entry was used to eliminate input error. All data were analyzed using SAS
9.1. The statistical analysis was carried out by Quintiles, Milan, Italy.
Continuous variables were summarized by descriptive statistics, and
categoric variables were summarized using counts of subjects and
percentages, with 95% confidence intervals (CIs). PFS and OS were
analyzed by the Kaplan–Meier method. Only patients who received at least
one dose of study treatment were included in the analysis [modified intent-
to-treat population (mITT)].
results
patients
During the first step of the trial, 63 patients were enrolled (21
for each tumor type). The clinical benefit (PR plus SD) was
original article Annals of Oncology
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24% (40% for melanoma, 19% for BC, and 24% for NSCLC);
therefore, the trial continued to the second step. In total, 162
patients (54 melanoma, 53 BC, and 55 NSCLC) were enrolled
across 25 study centers in Italy from December 2000 to October
2005. Eighty-three patients (37 melanoma, 22 breast, and 24
NSCLC) were enrolled from December 2000 to October 2002
and were treated on a 28-day cycle (schedule A). After the third
amendment, 79 patients (17 melanoma, 31 breast, and 31
NSCLC) were enrolled and treated on a 35-day cycle (schedule
B). Of these, 157 patients received at least one dose of study
drug and were included in the mITT analysis. Five patients (one
with melanoma, two with BC, and two with NSCLC) were
never treated and were not included in the analysis. Baseline
characteristics of the mITT population are shown in Table 1. In
the mITT population, 98 (62%) patients had received prior
chemotherapy for systemic disease and 41 (26%) patients had
received prior radiotherapy for the treatment of brain
metastases. Overall, 47 (30%) of the patients had received one
prior chemotherapy regimen, 19 (12%) had received two prior
regimens, and 32 (20%) had received three or more prior
regimens. Patients with BC were more heavily pretreated
compared with the other cohorts.
The total number of delivered cycles (both schedules) was
356. The primary reason for study withdrawal was disease
progression, accounting for 66% of patients on both schedules
(Table 2). Overall, 18% of the patients discontinued study
treatment because of AEs.
efficacy assessments
The overall objective response rate was 6% (one CR and nine
PR), and 31 (20%) patients in the mITT population had SD
(Table 3). The disease control rate was 32% (95% CI 20% to
46%) for melanoma (9% PR, 23% SD), 20% (95% CI 10% to
33%) for BC (4% PR, 16% SD), and 26% (95% CI 15% to
40%) for NSCLC (2% CR, 4% PR, 21% SD). However, the
majority of responses and SD were transient; only 13 (32%) of
the objective responses or SD were confirmed at a 4-week
follow-up scan. Response rate and disease control rate were
similar regardless of treatment schedule in patients with BC or
NSCLC. In patients with melanoma, the response rate was
marginally higher in patients treated on schedule A. Disease
control rate was also higher in patients who did not receive
prior WBRT. Among melanoma patients, the disease control
rate was 34% in patients who did not receive prior WBRT
compared with 22% in patients who did receive prior WBRT;
among BC patients, disease control was achieved only in
patients who did not receive prior WBRT (23% versus 0%);
and in NSCLC patients, the disease control rate was 29% in
patients who did not receive prior WBRT compared with 18%
in those who did. Because of the high number of missing data,
a formal analysis of neurological symptoms could not be
carried out.
Median PFS ranged from 1.9 months in the melanoma group
to 2.2 months in the NSCLC group (Figure 1A). Median NPFS
was similar and ranged from 2.1 to 2.5 months across all groups
and showed no significant difference with modification of the
treatment schedule. Median OS ranged from 3.3 months in the
melanoma group to 5.7 months in the NSCLC group (Figure
1B). Median OS was not reached in the BC group.
safety
The most commonly reported AEs were lymphopenia,
thrombocytopenia, nausea, vomiting, headache, and asthenia
(Table 4). The frequency of all AEs was lower with schedule B.
Thrombocytopenia resulted in dose reduction or treatment
discontinuation in 30 (19%) patients and occurred at
a lower frequency in patients treated on schedule B.
Lymphopenia was the most common grade 3 toxicity. Grade 4
hepatic toxicity and grade 4 leukopenia were rare and occurred
in £2% of patients.
Table 1. Patient demographics and baseline characteristics (modified
intent-to-treat population)
Characteristic Melanoma
(n = 53)
Breast cancer
(n = 51)
NSCLC
(n = 53)
Age, years, mean 6 standard
deviation
51.1 6 11.0 53.9 6 11.7 59.1 6 7.6
Sex
Male, n (%) 34 (64) 1 (2) 37 (70)
Body surface area,
mean 6 standard
deviation
1.8 6 0.2 1.7 6 0.2 1.7 6 0.2
Eastern Cooperative Oncology Group status, n (%)
0 29 (55) 17 (33) 23 (43)
1 18 (34) 24 (47) 25 (47)
2 6 (11) 10 (20) 5 (10)
Prior therapy for systemic disease, n (%)
Chemotherapy 21 (40) 41 (80) 36 (68)
Radiotherapy 2 (2) 20 (39) 12 (23)
Whole-brain radiotherapy,
n (%)
14 (26) 12 (24) 15 (28)
No. of prior chemotherapy regimens, n (%)
0 32 (60) 10 (20) 17 (32)
1 13 (24) 13 (25) 21 (40)
2 4 (8) 6 (12) 9 (17)
‡3 4 (8) 22 (43) 6 (11)
NSCLC, non-small-cell lung cancer.
Table 2. Reason for study withdrawal
No. of patients (%)
Melanoma
(n = 53)
Breast cancer
(n = 51)
NSCLC
(n = 53)
Relapse or progressive disease 38 (72) 33 (65) 33 (62)
Serious adverse events 9 (17) 8 (16) 12 (23)
Investigator’s decision 2 (4) 3 (6) 4 (8)
Withdrawal of consent 1 (2) 3 (6) 1 (2)
Other reason 3 (6) 4 (8) 3 (6)
NSCLC, non-small-cell lung cancer.
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discussion
This study represents the first large, multicenter study of
a dose-dense temozolomide regimen in patients with brain
metastases, in which patients were prospectively stratified by
primary tumor type. Although this study, designed in 2000, has
certain limitations because data were not collected on control
of systemic disease at baseline, and patients were not stratified
by RPA class, the results are no less important. The rationale for
the treatment regimen was based on several considerations.
First, temozolomide effectively crosses the blood–brain barrier
and has demonstrated good clinical activity against primary
brain tumors [11–13]. Second, dose-dense temozolomide
regimens may overcome resistance to alkylating agents.
The results of the present study demonstrated that this
regimen has activity in patients with brain metastases from all
three tumor types, particularly melanoma. In addition,
antitumor activity appeared to be greater in patients who had
not received prior irradiation for brain metastases and in
patients who were less heavily pretreated with chemotherapy
for systemic disease. Patients with BC had the lowest disease
control rate but were also more heavily pretreated than patients
with melanoma or NSCLC. The main limitation of this regimen
was that patients progressed quickly, and both PFS and OS
were relatively short. In addition, the regimen caused dose-
limiting thrombocytopenia in a subset of patients, which is
consistent with data reported in other studies with this regimen
[18, 25]. This is not surprising given that the majority of
patients had received prior chemotherapy for systemic disease.
This prompted lengthening of the cycle to allow a longer
recovery period; the amended treatment cycle reduced the
frequency of all AEs without compromising the survival benefit.
The limited activity and transient nature of the tumor
responses observed across tumor types in this study has been
documented in other trials of systemic chemotherapy for the
treatment of brain metastases (Table 5) [7, 8, 19, 20, 25–28].
There do not appear to be substantial differences in the median
OS achieved with different temozolomide schedules and other
experimental systemic chemotherapy regimens. However,
because of the relatively small numbers of patients in some
studies and variable prior treatment history, it is difficult to
compare results across studies. None the less, the survival data
from the present study are similar to those reported in other
trials of systemic chemotherapy.
In patients with BC, a variety of regimens have been
investigated for the treatment of brain metastases including
Table 3. Brain tumor response by tumor type and treatment schedule
Schedule A, n (%) [CI] Schedule B, n (%) [CI] Overall, n (%) [CI] Total, n (%)
Melanoma
(n = 36)
BC
(n = 22)
NSCLC
(n = 23)
Melanoma
(n = 17)
BC
(n = 29)
NSCLC
(n = 30)
Melanoma
(n = 53)
BC
(n = 51)
NSCLC
(n = 53)
N = 157
CR 0 0 0 0 0 1 (3) 0 0 1 (2) 1 (<1)
PR 4 (11) 1 (5) 1 (4) 1 (6) 1 (3) 1 (3) 5 (9) 2 (4) 2 (4) 9 (6)
SD 9 (25) 5 (23) 5 (22) 3 (18) 3 (10) 6 (20) 12 (23) 8 (16) 11 (21) 31 (20)
Disease control
(CR + PR + SD)
13 (36)
[21–54]
6 (27)
[11–50]
6 (26)
[10–48]
4 (24)
[7–50]
4 (14)
[4–32]
8 (27)
[12–46]
17 (32)
[20–46]
10 (20)
[10–33]
14 (26)
[15–40]
41 (26)
PD 23 (64)
[46–79]
16 (73)
[50–89]
17 (74)
[52–90]
13 (77)
[50–93]
25 (86)
[68–96]
22 (73)
[54–88]
36 (68)
[54–80]
41 (80)
[67–90]
39 (74)
[60–85]
116 (74)
CI, confidence interval; BC, breast cancer; NSCLC, non-small-cell lung cancer; CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease.
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Figure 1. Kaplan–Meier estimates of progression-free (A) and overall
survival (B) by tumor type.
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topotecan, temozolomide, cisplatin, and vinorelbine plus
mitoxantrone [8, 22, 28–30]. Trials of single-agent topotecan in
patients with metastatic BC demonstrated very modest clinical
activity, and further trials using this agent were not
recommended [31]. Single-agent temozolomide using the
standard 5-day regimen did not produce any objective
responses in patients with brain metastases from BC [27]. In
the present study, although the disease control rate was lowest
in the BC group, two patients achieved a PR. Overall, the results
of the present study indicate that single-agent temozolomide is
active, but it is probably not the optimal strategy for treating
brain metastases, particularly for BC.
More favorable outcomes have been achieved when
temozolomide was combined with radiotherapy, and there is
evidence to indicate that temozolomide may have
a radiosensitizing effect [32, 33]. Studies combining
temozolomide with WBRT reported response rates ranging
from 55% to 96% with median survival ranging from 15 to 36
weeks [34]. In a phase II trial of temozolomide (75 mg/m2/day)
administered concurrently with WBRT for 4 weeks followed by
six cycles of 200 mg/m2/day · 5 days every 28-day cycle in
patients with brain metastases from breast and lung cancer,
Antonadou et al. [35] reported a median survival of 36 weeks.
More recently, a phase II trial of temozolomide plus WBRT
followed by temozolomide maintenance (standard 5-day
schedule) reported a median OS of 52 weeks in patients with
brain metastases from NSCLC and other solid tumors,
including BC [30]. Similarly, Addeo et al. [36] demonstrated
that concomitant WBRT and temozolomide plus the standard
5-day maintenance temozolomide schedule was well tolerated
and produced an encouraging objective response rate (45%)
and a significant improvement in quality of life. The ongoing
SWS-SAKK-70/03 and RTOG-0320 randomized trials are
investigating WBRT with or without dose-dense temozolomide
in patients with brain metastases from NSCLC. It is hoped that
these studies will provide further clarification of the benefit of
combining WBRT with a dose-dense temozolomide regimen.
Combinations of WBRT with chemotherapy have also been
reported to yield high response rates in patients with brain
metastases from BC; however, this often fails to translate into
improved survival. In one study, WBRT plus topotecan resulted
in a 72% objective response rate, but median OS was only 17
weeks [22]. Similar results were obtained in a recent phase III
trial of WBRT with or without efaproxiral in patients with
brain metastases from breast or lung cancer; median OS in the
efaproxiral plus WBRT arm was 23 and 18 weeks for breast and
lung cancer patients, respectively [37].
Clinical strategies to control brain metastases must also
consider the biologic characteristics of the tumor and control of
extracranial disease. In fact, the long-term survival (>20
months) achieved in patients with brain metastases from
HER2-positive BC who were treated with trastuzumab-based
Table 4. Common adverse events (all grades)
Schedule A, n (%) Schedule B, n (%) All histologies, n (%)
(N = 157)Melanoma
(n = 36)
BC
(n = 22)
NSCLC
(n = 23)
Melanoma
(n = 17)
BC
(n = 29)
NSCLC
(n = 30)
Lymphopenia 15 (42) 7 (32) 10 (44) 1 (6) 6 (21) 6 (20) 45 (29)
Thrombocytopenia 12 (33) 6 (27) 15 (65) 1 (6) 6 (21) 6 (20) 46 (29)
Nausea 12 (33) 5 (23) 5 (22) 1 (6) 3 (10) 2 (7) 28 (18)
Vomiting 12 (33) 6 (27) 3 (13) 2 (12) 4 (14) 4 (13) 31 (20)
Headache 7 (19) 6 (27) 3 (13) 3 (18) 3 (10) 4 (13) 26 (17)
Asthenia 7 (19) 6 (27) 7 (30) 2 (12) 1 (3) 7 (23) 30 (19)
BC, breast cancer; NSCLC, non-small-cell lung cancer.
Table 5. Summary of efficacy of systemic therapy in patients with brain metastases
Study Primary tumor type Treatment N Disease control ratea (%) OS (months)
Agarwala et al. [26] Melanoma TMZ, 5 days 151 32 3.8
DeCOG/ADO [25] Melanoma TMZ, alternating weekly 45 15 4.3
Bernardo et al. [19] NSCLC Vinorelbine +
GEM + carboplatin
20 70 8.3
Cortes et al. [20] NSCLC PAC + cisplatin 25 38b 5.3
Trudeau et al. [27] Breast TMZ, alternating weekly 19 16 Not reported
Christodoulou et al. [28] Mixed TMZ, 5 days + cisplatin 32 47 5.5
Abrey et al. [7] Mixed TMZ, 5 days 34 50 6.6
Christodoulou et al. [8] Mixed TMZ, 5 days 24 21 4.5
Present study Melanoma TMZ, alternating weekly 53 32 3.3
NSCLC 53 26 5.7
Breast 51 20 Not reached
OS, overall survival; TMZ, temozolomide; NSCLC, non-small-cell lung cancer; GEM, gemcitabine; PAC, paclitaxel.
aDisease control rate = complete response + partial response + stable disease.
bIntracranial response rate.
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therapy may be attributed to better control of extracranial
disease [38, 39]. Several studies have also shown that small-
molecule tyrosine kinase inhibitors (e.g. lapatinib, gefitinib, and
erlotinib), which have systemic activity in tumors with specific
molecular phenotypes, are a viable option for treating brain
metastases [40–42]. Lapatinib has demonstrated activity against
brain metastases from HER2-positive BC, whereas gefitinib and
erlotinib were particularly effective in patients with brain
metastases from primary lung tumors harboring epidermal
growth factor receptor amplifications or mutations [40, 42].
Combining temozolomide with other therapeutic agents that
have demonstrated activity against systemic metastatic disease
could potentially enhance the clinical benefit in pretreated
patients with brain metastases.
In summary, this alternating weekly (7/14-day), dose-dense
temozolomide regimen is well tolerated and has antitumor
activity in patients with brain metastases from melanoma, BC,
and NSCLC and compares favorably with other temozolomide-
dosing schedules, particularly in patients with melanoma;
however, single-agent temozolomide is probably not the optimal
therapeutic strategy, especially in patients with NSCLC or BC.
The combination of temozolomide with WBRT or other agents
with CNS and systemic antitumor activity may improve clinical
outcome of patients with brain metastases. Larger studies of
dose-dense temozolomide plus concomitant WBRT are ongoing.
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